This brand name is authorized in Canada, United States
The drug MEPRON contains one active pharmaceutical ingredient (API):
1
Atovaquone
UNII Y883P1Z2LT - ATOVAQUONE
|
Atovaquone is a selective and potent inhibitor of the eukaryotic mitochondrial electron transport chain in a number of parasitic protozoa and the parasitic fungus P. jiroveci. The site of action appears to be the cytochrome bc1 complex (complex III). |
Below package inserts are available for further reading:
Title | Information Source | Document Type | |
---|---|---|---|
MEPRON Oral suspension | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
P01AX06 | Atovaquone | P Antiparasitic products, insecticides and repellents → P01 Antiprotozoals → P01A Agents against amoebiasis and other protozoal diseases → P01AX Other agents against amoebiasis and other protozoal diseases |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: CA | Health Products and Food Branch | Identifier(s): 02217422 |
Country: US | FDA, National Drug Code | Identifier(s): 0173-0547, 0173-0665 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.